[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

612.O1.6 Acute Lymphoblastic Leukemia - Biology and Pathophysiology

Oral and Poster Abstracts
Oral Session
Sunday, December 6, 2009: 4:30 PM-6:00 PM
353-355 (Ernest N. Morial Convention Center)
Moderators:
Jules P.P. Meijerink, PhD. and Mark Y Chiang, MD, PhD
4:30 PM
C-Myc, but Not Akt, Can Substitute for Notch in Lymphomagenesis

Mark Y Chiang, MD, PhD1, M. Eden Childs, B.A.1*, Candice Romany1*, Olga Shestova, Ph.D.2*, Jon Aster, MD, PhD3 and Warren S. Pear, MD, PhD1

1University of Pennsylvania, Philadelphia, PA
2Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
3Brigham and Women's Hosp., Boston, MA

4:45 PM
Acute T-Cell Leukemias Remain Dependent On Notch Signaling Despite PTEN and INK4A/ARF Loss

Hind Medyouf1, Xiuhua Gao2*, Florence Armstrong3*, Samuel Gusscott1*, Qing Liu, BS2*, Amanda Larson Gedman4*, Larry Matherly, PhD5*, Kirk R. Schultz, MD6, Francoise Pflumio, PhD3*, M. James You, MD, PhD7 and Andrew P. Weng, MD, PhD1

1British Columbia Cancer Agency, Vancouver, BC, Canada
2Hematopathology, UT MD Anderson Cancer Center, Houston, TX
3Laboratoire des cellules souches hématopoïétiques et leucémiques (LSHL)-IRCM, Commissariat a l'Energie Atomique, Fontenay-aux-Roses, France
4Graduate Program in Cancer Biology, Wayne State University School of Medicine, Detroit, MI
5Barbara Ann Karmanos Cancer Inst., Detroit, MI
6B.C. Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
7MD Anderson Cancer Center, Houston, TX

5:00 PM
Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of induction—A Children’s Oncology Group (COG) Study

Brent Wood, MD, PhD1, Stuart Winter, MD2, Kimberly Dunsmore, MD3, Elizabeth Raetz, MD4, Michael J. Borowitz, MD, PhD5, Meenakshi Devidas, PhD6*, Naomi J. Winick, MD7, William L. Carroll, MD8, Stephen P Hunger, MD9 and Mignon L. Loh, MD10

1Department of Laboratory Medicine, University of Washington, Seattle, WA
2Department of Pediatrics, University of New Mexico, Albuquerque, NM
3Health Sciences Center, University of Virginia, Charlottesville, VA
4New York University Langone Medical Center, New York, NY
5Hematologic Pathology, Johns Hopkins University, Baltimore, MD
6Department of Epidemiology & Health Policy Research, Children's Oncology Group & University of Florida College of Medicine, Gainesville, FL
7University of Texas Southwestern Medical Center, Dallas, TX
8New York University Cancer Institute, New York, NY
9Pediatric Heme/Onc/BMT, University of Colorado College of Medicine, Aurora, CO
10Pediatrics, University of California, San Francisco, San Francisco, CA

5:15 PM
Role of Survivin in Drug Resistant B-Cell Acute Lymphoblastic Leukemia

Eugene Park1*, Enzi Jiang, MD, PhD1*, Gregor von Levetzow2*, Cihangir Duy2*, Lars Klemm2*, Yao-Te Hsieh1*, Asha Kadavallore1*, Hong Ma, PhD3*, Yi Zhao, MD3*, Cu Nguyen3*, John Groffen, PhD4*, Nora Heisterkamp, PhD4*, Markus Muschen, MD2, Michael Kahn, PhD3* and Yong-Mi Kim, MD1

1Pediatrics, Division of Hematology and Oncology, Leukemia Research Program, CHLA-USC, Los Angeles, CA
2Leukemia Research Program, CHLA-USC, Los Angeles, CA
3Department of Biochemistry and Molecular Biology, Department of Molecular Pharmacology and Toxicology, The Eli and Edythe Broad Center for Regenerative Medicine and Stem cell Research at USC, Los Angeles, CA
4Pediatrics, CHLA-USC, Los ANgeles, CA

5:30 PM
DOWN’S Syndrome Acute Lymphoblastic LEUKEMIA: A HIGHLY Heterogeneous DISEASE DRIVEN by an Aberrant CRLF2/JAK2 Cooperation – A REPORT FROM the Ibfm-STUDY GROUP

Libi Hertzberg, MSc1*, Elena Vendramini2*, Ithamar Ganmore, BSc3*, Giovanni Cazzaniga4, Maike Schmitz, MSc5*, Ruth Shiloh, BSc3*, Jane Chalker6*, Ilaria Iacobucci7*, Chen Shochat8*, Sharon Zeligson1*, Gunnar Cario9*, Martin Stanulla, MD10*, Sabine Strehl, PhD11*, Lisa J Russel, PhD12*, Christine Harrison13, Beat Bornhauser, PhD5*, Akinori Yoda, Ph.D.14*, Gideon Rechavi, MD, PhD15*, Dani Bercovich, PhD8*, Arndt Borkardt16*, Helena Kempski17*, Geertruy te Kronnie, PhD2*, Jean-Pierre Bourquin, MD, PhD18, Eytan Domany, PhD19* and Shai Izraeli, MD20

1Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, Israel
2Pediatrcs, University of Padova, Padova, Italy
3Chaim Sheba Medical Center, Israel
4Pediatric Clinic University of Milan Bicocca, M.Tettamanti Research Center, Monza, Italy
5Department of Pediatric Oncology,, University Children's Hospital, University of Zurich
6Institue of Child Health, UCL
7Department of Hematology/Oncology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy
8Migal–Galilee Biotechnology Center, Israel
9Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
10Dpt of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany
11Ccri, Children Cancer Research Institute St Anna Kinderspital, Vienna, Austria
12Northern Institute for Cancer Research, NewCastle, United Kingdom
13Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
14Dana-Farber Cancer Institute, Boston, MA
15Cancer Research Center, Sheba Medical Center, Tel-Hashomer, Israel
16Heinrich Heine University, Dusseldorf, Germany
17Pediatric Cytogenetics Malignancy Unit, Great Ormond Street Hospital, London
18Paediatric Haematology/Oncology, University of Zurich, Zurich, Switzerland
19Weizmann Institute of Sciences
20Chaim Sheba Medical Center, Ramat Gan, Israel

5:45 PM
PAX5 Wild-Type without IKZF1 (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party

Ilaria Iacobucci, PhD1*, Cristina Papayannidis1*, Francesca Paoloni2*, Annalisa Lonetti1*, Markus Muschen3, Marco Vignetti4*, Daniela Cilloni, MD5, Simona Soverini, PhD1*, Francesca Messa5*, Stefania Paolini1*, Sabina Chiaretti4*, Viviana Guadagnuolo1*, Paola Fazi2*, Antonella Vitale4*, Giovanna Meloni4*, Marco Gobbi, MD6*, Michele Malagola7, Giuseppe Saglio, MD5, Fabrizio Pane, MD8*, Michele Baccarani1*, Robin Foà4* and Giovanni Martinelli, MD1*

1Department of Hematology/Oncology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy
2GIMEMA Data Center, GIMEMA Foundation, Rome, Italy
3Leukemia Research Program, Childrens Hospital Los Angeles, Los Angeles, CA
4Division of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy
5University at Orbassano, Turin, Department of Clinical and Biological Science, Orbassano, Turin, Italy
6Dipartimento di Ematologia e Oncologia, Università di Genova, Italy, Genova, Italy
7Chair of Hematology, University of Brescia, Brescia, Italy
8Haematology Unit and Dep. of Biochemistry and Medical Biotechnology, CEINGE-Advanced Biotechnology, University of Naples “Federico II”, Naples, Italy

*signifies non-member of ASH